Rethinking ‘Exhausted’ T Cells: Gilbert Herrera Named Inaugural Ellen & Bernard Marson Fellow
The fellowship provides three years of funding for graduate students pursuing groundbreaking immunology research.
The Parker Institute for Cancer Immunotherapy at Gladstone Institutes
Immunotherapy has the potential to revolutionize cancer treatment by training the immune system to recognize and eliminate malignant cells. At the Parker Institute for Cancer Immunotherapy (PICI) at Gladstone Institutes, researchers are using the latest genomic technologies to learn how to control human immune cells precisely and design next-generation immunotherapy approaches for clinical testing.
PICI, the leading network of immuno-oncology expertise in the world, launched this research center at Gladstone in 2022 to support bold, high-risk scientific research and bridge academia and biotech, in part through the formation of companies founded on novel cancer therapies.
Working closely with other eminent scientists within the PICI network, Gladstone investigators harness the power of genomics and CRISPR technology to understand what governs the function of immune cells. Their goal is to re-engineer these cells and turn them into living and genetically-programmable drugs to treat cancer.
Director
Members
Alisa Dietl, Parker Scholar
Rosmely Hernandez, PICI RISE Scholar
Karin Pelka, Investigator
Anna Ralser, Parker Scholar
Affiliated Researchers
Support Discovery Science
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
DONATE NOWLatest News
Science in Seconds | An Unprecedented Map of Human Immune Cells
In this video, Gladstone scientists Emma Dann and Ronghui Zhu explain how their new study offers a powerful framework for designing cancer immunotherapies and treating autoimmune conditions.
Read
Scientists Decode Gene Circuits of Human Immunity, Fueling New Era of Disease Research
An unprecedented map of 22 million immune cells provides the functional rulebook for virtual biology and next-generation immunotherapies.
Read
New Toolkit Turns Macrophages Into Better Cancer Fighters
Gladstone and UCSF scientists developed a method to genetically edit myeloid cells, immune cells that act as the body’s first responders.
Read
New CRISPR Screening Platform Boosts Power of Immunotherapy Against Solid Tumors
A new screening platform uncovers gene edits that enhance CAR-T cells’ ability to infiltrate and eliminate solid tumors.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now